Frontline brentuximab vedotin and CHP (A+CHP) in patients (pts) with peripheral T-cell lymphoma with less than 10% CD30 expression: Results from the phase 2 SGN35-032 study Meeting Abstract
| Authors: | Iyer, S. P.; Jagadeesh, D.; Domingo-Domenech, E.; Benedetti, F.; Izquierdo, A. R.; Bouabdallah, K.; Vitolo, U.; Illidge, T. M.; Liu, J.; Shaikh, E.; Horwitz, S. M. |
| Abstract Title: | Frontline brentuximab vedotin and CHP (A+CHP) in patients (pts) with peripheral T-cell lymphoma with less than 10% CD30 expression: Results from the phase 2 SGN35-032 study |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557401716 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.7069 |
| Notes: | Meeting Abstract: 7069-- Source: Wos |
